A detailed characterization of drug resistance during darunavir/ritonavir monotherapy highlights a high barrier to the emergence of resistance mutations in protease but identifies alternative pathways of resistance.
Abdullahi A, Diaz AG, Fopoussi OM, Beloukas A, Defo VF, Kouanfack C, Torimiro J, Geretti AM.
J Antimicrob Chemother. 2024 Feb 01. 79(2):339-348. PMID: 38153241